ALZHEIMERS DRUGS MARKET ANALYSIS

Alzheimers Drugs Market Size and Trends

Global Alzheimer’s drugs market is estimated to be valued at USD 5.10 Bn in 2024 and is expected to reach USD 10.11 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 10.3% from 2024 to 2031.

To learn more about this report, Request sample copy

Global Alzheimer’s drugs market growth is driven by increasing incidence and prevalence of Alzheimer’s disease worldwide due to rising geriatric population. New product launches by key players can also drive the market growth. The launch of new drugs that target the underlying causes and slow disease progression rather than just control symptoms can drive the market growth. However, patent expiry of blockbuster drugs, high costs associated with drug development and lack of curative drugs ar can hamper the market growth during the forecast period.

Aging Population and Prevalence of Alzheimer's

Due to rising life expectancy, there has been increase in number of elderly people aged 65 years and over. According to WHO, the proportion of the world's population over 60 years will nearly double from 12% to 22% between 2015 and 2050. Elderly population is particularly susceptible to neurodegenerative conditions such as Alzheimer's and dementia due to natural age-related cognitive decline. Alzheimer's disease is the most common cause of dementia among older adults. As more people survive into their 80s and beyond, even a small increase in diagnosis rates in the very old can cause a dramatic rise in prevalence numbers. In 2017, according to a report, around 50 million people have dementia worldwide, and Alzheimer's disease accounts for 60–70% of cases. Growing elderly populations can increase Alzheimer's cases without effective prevention or cure strategies.

To learn more about this report, Request sample copy

Novel Drug Targets and Pipeline Progress

After multiple past failures in treatment development for Alzheimer's, the currently approved medicines can only manage symptoms temporarily without altering disease progression. There has been promising pipeline activity that explores novel mechanisms and molecular targets beyond the amyloid hypothesis. Several companies are developing disease-modifying drugs targeting tau tangles, neuroinflammation, synaptic dysfunction, and other pathways increasingly implicated in Alzheimer's pathology. Large late-stage trials are ongoing to evaluate anti-amyloid antibodies as well as anti-tau antibodies and small molecules for preventing or slowing cognitive decline. Some potential first-in-class therapies for early Alzheimer's include anti-Tau antibody crenezumab from Genentech and anti-amyloid gamma secretase modulator verubecestat from Merck.